Cancer vaccine

North America Cancer Vaccines Market Report 2020-2027 Featuring Leading Players - AstraZeneca, GSK, Aduro Biotech, Pfizer, Sanofi, Bristol-Myers Squibb, Moderna, OncBioMune, MaxiVAX, Nouscom

Retrieved on: 
Wednesday, December 9, 2020
Vaccination, Medical specialties, Medicine, Vaccine, Clinical medicine, Cancer vaccine

7.2 Cancer Vaccines Market Share, by Technology, 2019 and 2027 (%)

Key Points: 
  • 7.2 Cancer Vaccines Market Share, by Technology, 2019 and 2027 (%)
    8.2 Cancer Vaccines Market Revenue Share, by Type (2019 and 2027)
    9.2 Cancer Vaccines Market Revenue Share, by Indication (2019 and 2027)
    10.2 Cancer Vaccines Market Revenue Share, by End Use (2019 and 2027)
    13.2 Growth Strategies Done by the Companies in the Market, (%)

Asia Pacific Cancer Vaccines Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Technology, Type, Indication, End User - ResearchAndMarkets.com

Retrieved on: 
Friday, December 4, 2020
Infectious diseases, Health, Other Technology, Technology, Oncology, Vaccination, Medical specialties, Vaccine, Clinical medicine, Medicine, Cancer vaccine

7.2 Cancer Vaccines Market Share, by Technology, 2019 and 2027 (%)

Key Points: 
  • 7.2 Cancer Vaccines Market Share, by Technology, 2019 and 2027 (%)
    8.2 Cancer Vaccines Market Revenue Share, by Type (2019 and 2027)
    9.2 Cancer Vaccines Market Revenue Share, by Indication (2019 and 2027)
    10.2 Cancer Vaccines Market Revenue Share, by End Use (2019 and 2027)
    13.2 Growth Strategies Done by the Companies in the Market, (%)

Europe Cancer Vaccines Market Forecast to 2027 with COVID-19 Impact Insights - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 3, 2020
Health, Biotechnology, Vaccination, Medical specialties, Medicine, Clinical medicine, Vaccine, Cancer vaccine, Viral vector, Vaccine therapy, Therapeutic vaccines

Based on technology, the Cancer Vaccines market is segmented into in dendritic cells cancer vaccines, recombinant cancer vaccines, antigen cancer vaccines, whole cell cancer vaccines, viral vector cancer vaccines.

Key Points: 
  • Based on technology, the Cancer Vaccines market is segmented into in dendritic cells cancer vaccines, recombinant cancer vaccines, antigen cancer vaccines, whole cell cancer vaccines, viral vector cancer vaccines.
  • The in recombinant cancer vaccines segment held the largest share of the market in 2019.
  • Moreover, recombinant cancer vaccines is estimated grow at the highest CAGR in the market during the forecast period.
  • Market growth in Europe Cancer Vaccines is mainly due to factors such as increasing prevalence of cancer and rising government initiatives to prevent cancer.

North America Cancer Vaccines Market 2020-2027: COVID-19 Impact and Analysis By Technology, Type, Indication, End User - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 2, 2020
Health, Pharmaceutical, Vaccination, Medical specialties, Vaccine, Clinical medicine, Medicine, Cancer vaccine

7.2 Cancer Vaccines Market Share, by Technology, 2019 and 2027 (%)

Key Points: 
  • 7.2 Cancer Vaccines Market Share, by Technology, 2019 and 2027 (%)
    8.2 Cancer Vaccines Market Revenue Share, by Type (2019 and 2027)
    9.2 Cancer Vaccines Market Revenue Share, by Indication (2019 and 2027)
    10.2 Cancer Vaccines Market Revenue Share, by End Use (2019 and 2027)
    13.2 Growth Strategies Done by the Companies in the Market, (%)

City of Hope Has Developed a Cancer-killing Virus That Activates Immune System, Helps Eliminate Colon Cancer

Retrieved on: 
Tuesday, December 1, 2020
Health, Science, Other Science, Research, Oncology, Medical specialties, Medicine, Clinical medicine, Cancer, Oncolytic virus, Immune system, American Association for Cancer Research, Virotherapy, Cancer vaccine, Cancer immunotherapy

A cancer-killing virus that City of Hope scientists developed could one day improve the immune systems ability to eradicate tumors in colon cancer patients, reports a new study in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.

Key Points: 
  • A cancer-killing virus that City of Hope scientists developed could one day improve the immune systems ability to eradicate tumors in colon cancer patients, reports a new study in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.
  • Our oncolytic virus trains the immune system to target a specific cancer cell.
  • City of Hope has licensed CF33 to Imugene Limited , a company developing novel therapies that activate the immune system against cancer.
  • City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases.

Torigen Announces Positive Results for Dogs Administered the Company's Autologous Cancer Vaccine

Retrieved on: 
Tuesday, December 1, 2020
Clinical medicine, Vaccination, Medical specialties, Medicine, Cancer vaccine, Immunotherapy, Vaccine, Therapeutic vaccines, Draft:Whole-cell cancer vaccine

FARMINGTON, Conn., Dec. 1, 2020 /PRNewswire-PRWeb/ -- Torigen Pharmaceuticals Inc. , an animal health biologics company, today announced positive preliminary results supporting the therapeutic potential of the company's experimental Autologous Cancer Vaccine for treating metastatic hemangiosarcoma (HSA) in dogs.

Key Points: 
  • FARMINGTON, Conn., Dec. 1, 2020 /PRNewswire-PRWeb/ -- Torigen Pharmaceuticals Inc. , an animal health biologics company, today announced positive preliminary results supporting the therapeutic potential of the company's experimental Autologous Cancer Vaccine for treating metastatic hemangiosarcoma (HSA) in dogs.
  • The study revealed a greater than 3-fold increase in survival of the dogs treated with their Autologous Cancer Vaccine over those receiving surgery alone.
  • About Torigen's Autologous Cancer Vaccine:
    Torigen's Autologous Cancer Vaccine is a form of active immunotherapy consisting of cells harvested from the patient's own tumor making this a cancer-type agnostic treatment.
  • To date, more than 800 dogs across the United States have been treated with their Autologous Cancer Vaccine.

OBI Pharma Announces Presentations at ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine

Retrieved on: 
Thursday, November 19, 2020
Fictional characters, Fiction, Obi, Cancer vaccine

Theseresults will be presented by the lead investigators of OBI Pharma's novel anti-Globo H therapeutic cancer vaccine, OBI-833.

Key Points: 
  • Theseresults will be presented by the lead investigators of OBI Pharma's novel anti-Globo H therapeutic cancer vaccine, OBI-833.
  • "Based upon our anti-Globo H targeted approaches in cancers of high unmet needs, OBI Pharma is proud to have presentations on the progress of our trial presented at ESMO-Asia 2020 for our novel therapeutic cancer vaccine, OBI-833."
  • Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma stated, "In the trial, OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses.
  • Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau.

OBI Pharma Announces Presentations at ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine

Retrieved on: 
Thursday, November 19, 2020
Fictional characters, Fiction, Obi, Cancer vaccine

Theseresults will be presented by the lead investigators of OBI Pharma's novel anti-Globo H therapeutic cancer vaccine, OBI-833.

Key Points: 
  • Theseresults will be presented by the lead investigators of OBI Pharma's novel anti-Globo H therapeutic cancer vaccine, OBI-833.
  • "Based upon our anti-Globo H targeted approaches in cancers of high unmet needs, OBI Pharma is proud to have presentations on the progress of our trial presented at ESMO-Asia 2020 for our novel therapeutic cancer vaccine, OBI-833."
  • Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma stated, "In the trial, OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses.
  • Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau.

Mount Sinai Researchers Discover How to Boost Efficacy of Vaccine Designed to Prevent Melanoma Recurrence

Retrieved on: 
Monday, November 16, 2020
Medicine, Clinical medicine, Medical specialties, Vaccination, Vaccines, Cancer vaccines, Cancer vaccine, Vaccine, Melanoma, Oncophage, Herpes simplex research

These results are important because most cancer vaccine trials have failed to show clinical efficacy.

Key Points: 
  • These results are important because most cancer vaccine trials have failed to show clinical efficacy.
  • Sixty patients who had stage 2 or 3 melanoma, and whose cancer was successfully removed via surgery, received the vaccine.
  • Half of the patients received the vaccine alone while the other half received the vaccine with Flt3L and poly-ICLC.
  • Researchers also plan to follow trial participants over time and measure how many have cancer recurrence to further study the vaccine's efficacy in each group.

Moderna Announces Clinical Updates on Personalized Cancer Vaccine Program

Retrieved on: 
Wednesday, November 11, 2020
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Medicine, Medical specialties, Vaccination, Vaccines, Life sciences, Medical research, Moderna, Cancer vaccines, Cancer vaccine, Vaccine, Moderna’s Immuno-Oncology Programs, Moderna

Moderna also announced that Dr. Praveen Aanur has joined Moderna as Vice President, Therapeutic Area Head for Oncology Development.

Key Points: 
  • Moderna also announced that Dr. Praveen Aanur has joined Moderna as Vice President, Therapeutic Area Head for Oncology Development.
  • We are encouraged by these interim data from our personalized cancer vaccine program, which involves designing and manufacturing a unique vaccine for each patient based on their specific tumor, said Stephen Hoge, M.D., President of Moderna.
  • This study demonstrates the ability of Modernas mRNA personalized cancer vaccine to elicit clinical activity when given in combination with pembrolizumab.
  • Moderna develops and manufactures these investigational PCVs at its personalized vaccines unit within its Massachusetts manufacturing facility.